

Approved for
Use by WHO

lowest price
offered in the US

<10\$ or >20\$

\$?

Vaccine name

Manufacturer



vaccine



Immune
Response

Quick Mechanism Summary

? Vaccine class

Quick description

Outline color indicates the availability
of the data :

- published (peer-reviewed),
- not published (not reviewed
by independant scientists)

Broken down by severity (defined
by each trial):

- severe case (without hospitalisation)
- symptomatic: fever, cough etc...
often confirmed by PCR test

⊕ **Efficacy** : --% (vs severe cases)
 --% (vs symptomatic cases)

The efficacy assessment is different for each trial/vaccine so try not
to compared them too much..

📄 **Dosing** : # of doses and how far apart


📄 **Storage** : conditions of storage

@LaPipette.labs

mRNA-1273

Moderna

\$\$\$



② Encapsulated mRNA Vaccine

mRNA encoding for the Spike protein is protected in a lipid nanoparticle (like a soap bubble). Once absorbed, the cell expresses the Spike protein resulting in an immune response.

⊕ **Efficacy :** Phase III **100%** (vs severe cases*)
Phase III **94%** (vs symptomatic cases*)

💊 **Dosing :** 0.5mL - 2 doses - 28 days apart

📦 **Storage :** -20°C - 6 months
+2-8°C - 30 days

@LaPipette.labs


Last updated on 16/04/21

*US trial - 28 days after vaccination

BNT162b2 / Comirnaty

\$\$

BioNTech/Pfizer



② Encapsulated mRNA Vaccine

mRNA encoding for the Spike protein is protected in a lipid nanoparticle (like a soap bubble). Once absorbed, the cell expresses the Spike protein resulting in an immune response.

⊕ **Efficacy :**

Phase III	100%	(vs severe cases*)
Phase III	95%	(vs symptomatic cases*)
Qatar study	75%	(vs B.1.351 “SA” variant)

💊 **Dosing :** 0.3mL - 2 doses - 21 days apart

📦 **Storage :** -70°C - 6 months (-20°C - 2 weeks)
+2-8°C - 5 days

@LaPipette.labs


Last updated on 09/05/21

*international trial - 21 days after vaccination

AZD1222 / Vaxzevria (Covishield - India)



Oxford/AstraZeneca



Viral Vector Vaccine

dsDNA encoding for the Spike protein is protected in a safe virus. The infected cell expresses the Spike protein which leads to an immune response.

⊕ **Efficacy :**

Phase III	100%	(vs severe cases*)
Phase III	82**%	(vs symptomatic cases*)
Phase II	10%	(vs B.1.351 “SA” variant*)

📄 **Dosing :** 0.5mL - 2 doses - *12 weeks apart

📦 **Storage :** +2-8°C - 6 months

@LaPipette.labs


Last updated on 16/04/21

* when prime - boost doses injected at +12 weeks

**international trials

JNJ-78436735 / Ad26.COV2.S

Janssen / J&J



Viral Vector Vaccine

dsDNA encoding for the Spike protein is protected in a safe virus. The infected cell expresses the Spike protein which leads to an immune response.

⊕ **Efficacy :**

Phase III	100%	(vs hospitalisation*)
Phase III	74%	(vs symptomatic to severe*)
Phase III	64%	(vs B.1.351 "SA" variant*)

💊 **Dosing :** 0.5mL - 1 dose

📦 **Storage :** +2-8°C - 3 months
-20°C - 2 years


@LaPipette.labs

Last updated on 09/05/21

*US trial - 28 days after vaccination - CDC report

Sputnik V / Gam-Covid-Vac

Gamaleya



Viral Vector Vaccine

dsDNA encoding for the Spike protein is protected in a safe virus. The infected cell expresses the Spike protein which leads to an immune response.

⊕ **Efficacy :** Phase III **100%** (vs severe cases*)
Phase III **92%** (vs confirmed cases*)

💊 **Dosing :** 0.5mL - 2 doses - 21 days apart

📦 **Storage :** +2-8°C - 6 months
-20°C - 2 years


@LaPipette.labs

Last updated on 16/04/21

* Russian trial - 21 days after vaccination

Convitecia / Ad5-nCoV

CanSino Bio



Viral Vector Vaccine

dsDNA encoding for the Spike protein is protected in a safe virus. The infected cell expresses the Spike protein which leads to an immune response.

⊕ **Efficacy :**

Phase III

90% (vs severe cases*)

Phase III

65% (vs symptomatic cases*)

📄 **Dosing :** 1 dose

📦 **Storage :** +2-8°C


@LaPipette.labs

Last updated on 16/04/21

* International trial - not published data

NVX-CoV2373

Novavax





Subunit Vaccine

Nanoparticles are coated with synthetic spike proteins. An additional element called adjuvant is added which allows to boost the immune reaction.

⊕ **Efficacy :**

Phase III	100%	(vs severe cases)
Phase III	89%	(vs symptomatic cases*)
Phase IIb	51%	(B.1.351 “SA” variant)

 **Dosing :** 0.5mL - 2 doses - 21 days apart

 **Storage :** +2-8°C - 6 months
-20°C for 2 years

@LaPipette.labs


Last updated on 06/05/21

* average. 96% against the “original” strain (D614G)

BBIBP-CorV




\$\$\$

Sinopharm



Inactivated Virus Vaccine

SARS-CoV2 is chemically inactivated (with a chemical called beta-propiolactone•) so it cannot replicate but all the proteins remain intact.

 **Efficacy :**  **78%** (vs hospitalisation*)
 **78%** (overall efficacy*)

 **Dosing :** 2 doses - 21 days apart

 **Storage :** +2-8°C


@LaPipette.labs

Last updated on 08/09/21

* International trial - WHO Report



CoronaVac SinoVac

\$\$\$



Inactivated Virus Vaccine

SARS-CoV2 is chemically inactivated (with a chemical called beta-propiolactone•) so it cannot replicate but all the proteins remain intact.

🎯 **Efficacy :**  **100%** (vs severe cases*)
 **83%** (vs symptomatic cases*)

💊 **Dosing :** 2 doses - 14 days apart

📦 **Storage :** +2-8°C

@LaPipette.labs


Last updated on 16/04/21

* Unpublished Phase III results from Turkey

BBV152 / Covaxin

\$\$(\$\$)

Bharat Biotech



Inactivated Virus Vaccine

SARS-CoV2 is chemically inactivated (with a chemical called beta-propiolactone•) so it cannot replicate but all the proteins remain intact.

 **Efficacy :**  **81%** (vs symptomatic cases*)

 **Dosing :** 2 doses - 28 days apart

 **Storage :** +2-8°C

@LaPipette.labs

Last updated on 16/04/21

* Indian trial - not published data